{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:19:48Z","timestamp":1793351988220,"version":"4.5.0"},"reference-count":197,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001236","name":"Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001236","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jmii.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T13:17:15Z","timestamp":1647436635000},"page":"359-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms"],"prefix":"10.1016","volume":"55","author":[{"given":"Cheng Len","family":"Sy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-168X","authenticated-orcid":false,"given":"Tu-Hsuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7155-6802","authenticated-orcid":false,"given":"Ing-Moi","family":"Hii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3010-2767","authenticated-orcid":false,"given":"Yu-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Lien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-9500","authenticated-orcid":false,"given":"Pei-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-7861","authenticated-orcid":false,"given":"Ching-Lung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hao","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ju","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Fang","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-2414","authenticated-orcid":false,"given":"Susan Shin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Shen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ching","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2022.02.001_bib1","series-title":"Centers for Disease C, Prevention, National Center for Emerging Z et\u00a0al.","article-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.jmii.2022.02.001_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib7","unstructured":"Taiwan C.D.C. Taiwan Nosocomial Infections Surveillance System (TNIS) 20092009; Taiwan Centers for Disease Control(https:\/\/www.cdc.gov.tw\/En\/File\/Get\/v6rNFa_LQPGg0qOffOYbhw (Access Date Access 2009, date last accessed)."},{"key":"10.1016\/j.jmii.2022.02.001_bib8","unstructured":"Taiwan C.D.C. Taiwan Healthcare associated infections and Antimicrobial resistance Surveillance (THAS)(previously known as Taiwan Nosocomial Infections Surveillance System TNIS) 20202020; Taiwan Centers for Disease Control(https:\/\/www.cdc.gov.tw\/En\/File\/Get\/rQPhOnWeQkOXljor7MUrvA (Access Date Access 2020, date last accessed)."},{"key":"10.1016\/j.jmii.2022.02.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jinf.2011.12.008","article-title":"Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States","volume":"64","author":"Wisplinghoff","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2022.02.001_bib12","doi-asserted-by":"crossref","first-page":"e01110","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","article-title":"Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis","volume":"47","author":"Du","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jmii.2022.02.001_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5414\/CP203102","article-title":"Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii","volume":"56","author":"Qin","year":"2018","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jmii.2022.02.001_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052349","article-title":"Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients","volume":"7","author":"Shields","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2022.02.001_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000356004","article-title":"Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"59","author":"Garnacho-Montero","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jmii.2022.02.001_bib19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2014.01.016","article-title":"Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia","volume":"43","author":"Khawcharoenporn","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib20","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin\u2013sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.jmii.2022.02.001_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12879-016-1717-6","article-title":"Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"16","author":"Ye","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib22","doi-asserted-by":"crossref","first-page":"908 e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012278","article-title":"Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium?","volume":"97","author":"Jean","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jmii.2022.02.001_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jmii.2014.08.009","article-title":"Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization","volume":"49","author":"Hsieh","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2016.07.007","article-title":"Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients","volume":"48","author":"Tsioutis","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2022.02.001_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jmii.2013.05.007","article-title":"Synergy of imipenem\/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii","volume":"47","author":"Leu","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib30","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1128\/AAC.01230-13","article-title":"Systematic review and meta-analysis of in\u00a0vitro synergy of polymyxins and carbapenems","volume":"57","author":"Zusman","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib31","doi-asserted-by":"crossref","first-page":"e01989","DOI":"10.1128\/AAC.01989-18","article-title":"Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in\u00a0vitro pharmacokinetic\/pharmacodynamic model","volume":"63","author":"Bian","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157757","article-title":"Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model","volume":"11","author":"Fan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2022.02.001_bib33","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1080\/22221751.2020.1822757","article-title":"Association of capsular types with carbapenem resistance, disease severity, and mortality in Acinetobacter baumannii","volume":"9","author":"Hsieh","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1469-0691.2009.03040.x","article-title":"Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study","volume":"16","author":"Korbila","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib37","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","article-title":"Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study","volume":"27","author":"Feng","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jmii.2019.08.007","article-title":"Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"53","author":"Zheng","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. Baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jmii.2022.02.001_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/1120009X.2020.1764282","article-title":"The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates","volume":"32","author":"Li","year":"2020","journal-title":"J Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/IDR.S172137","article-title":"Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis","volume":"11","author":"Jiang","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib42","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","article-title":"Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in\u00a0vitro synergism is not associated with better clinical outcomes","volume":"26","author":"Nutman","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib43","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib44","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1177\/0300060519879336","article-title":"Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem","volume":"47","author":"Park","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jmii.2022.02.001_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/antibiotics9100647","article-title":"A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis","volume":"9","author":"Katip","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jmii.2022.02.001_bib46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/cid\/ciy988","article-title":"Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup Analysis of a randomized clinical trial","volume":"69","author":"Dickstein","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.jmii.2022.02.001_bib49","doi-asserted-by":"crossref","first-page":"ofx176","DOI":"10.1093\/ofid\/ofx176","article-title":"Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"4","author":"Cai","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib50","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 Years from the SENTRY antimicrobial surveillance program, 1997-2016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13756-018-0422-1","article-title":"Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: recent trends based on national surveillance reports","volume":"7","author":"Chiang","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jmii.2022.02.001_bib52","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/IDR.S174876","article-title":"Carbapenem-resistant and cephalosporin-susceptible Pseudomonas aeruginosa: a notable phenotype in patients with bacteremia","volume":"11","author":"Li","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib53","doi-asserted-by":"crossref","first-page":"e01243","DOI":"10.1128\/AAC.01243-16","article-title":"Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure","volume":"61","author":"Buehrle","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9040153","article-title":"Carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa in urinary tract infections: opportunity for colistin sparing","volume":"vol. 9","author":"Gajdacs","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jmii.2022.02.001_bib55","doi-asserted-by":"crossref","first-page":"e02400","DOI":"10.1128\/AAC.02400-17","article-title":"Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis","volume":"62","author":"Britt","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib56","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/AAC.00115-10","article-title":"Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms","volume":"54","author":"Martinez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib58","doi-asserted-by":"crossref","first-page":"106158","DOI":"10.1016\/j.ijantimicag.2020.106158","article-title":"Use of continuous-infusion ceftolozane\/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature","volume":"56","author":"Sheffield","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib59","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jmii.2022.02.001_bib60","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib61","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1128\/AAC.00844-15","article-title":"Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods","volume":"59","author":"Nelson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib62","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/cid\/ciw684","article-title":"The effectiveness and safety of high-dose colistin: prospective cohort study","volume":"63","author":"Benattar","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib63","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/cis909","article-title":"Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia","volume":"56","author":"Vicari","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib64","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc2358","article-title":"Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients","volume":"7","author":"Markou","year":"2003","journal-title":"Crit Care"},{"key":"10.1016\/j.jmii.2022.02.001_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","article-title":"Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections","volume":"37","author":"Montero","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2022.02.001_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1469-0691.2004.01043.x","article-title":"Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic","volume":"11","author":"Michalopoulos","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib67","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1128\/AAC.00494-15","article-title":"Polymyxin B in combination with antimicrobials lacking in\u00a0vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections","volume":"59","author":"Rigatto","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jmii.2022.02.001_bib69","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib70","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib71","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/INF.0000000000002847","article-title":"Evidence of dose variability and dosing below the FDA and EMA recommendations for intravenous colistin (polymyxin E) use in children and neonates","volume":"39","author":"Chin","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jmii.2022.02.001_bib72","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/cid\/ciz067","article-title":"Population pharmacokinetics of intravenous colistin in pediatric patients: implications for the selection of dosage regimens","volume":"69","author":"Ooi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12879-016-2117-7","article-title":"Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa","volume":"17","author":"Sorli","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12866-016-0719-2","article-title":"Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan","volume":"16","author":"Kao","year":"2016","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jmii.2014.01.005","article-title":"Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections","volume":"49","author":"Lin","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib76","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijantimicag.2019.06.009","article-title":"Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018","volume":"54","author":"Lee","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib77","author":"Liu","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib78","unstructured":"C.L.S.I. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100-S31 2021."},{"key":"10.1016\/j.jmii.2022.02.001_bib79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/mdr.2010.0115","article-title":"Prevalence and characteristics of ertapenem-resistant Klebsiella pneumoniae isolates in a Taiwanese university hospital","volume":"17","author":"Wu","year":"2011","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib81","article-title":"Carbapenem-nonsusceptible enterobacteriaceae in Taiwan","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2022.02.001_bib82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmii.2014.05.010","article-title":"Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan","volume":"48","author":"Chang","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib83","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1038\/s41598-018-26691-z","article-title":"Carbapenem nonsusceptible Klebsiella pneumoniae in Taiwan: dissemination and increasing resistance of carbapenemase producers during 2012-2015","volume":"8","author":"Chiu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2022.02.001_bib84","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3389\/fmicb.2018.02888","article-title":"Carbapenem-resistant enterobacteriaceae infections: Taiwan aspects","volume":"9","author":"Jean","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib85","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1179\/joc.2009.21.6.621","article-title":"Emergence of carbapenem-resistant Escherichia coli in Taiwan: resistance due to combined CMY-2 production and porin deficiency","volume":"21","author":"Chia","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/1471-2334-13-599","article-title":"Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan","volume":"13","author":"Ma","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1399-3062.2011.00688.x","article-title":"Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation","volume":"14","author":"Bergamasco","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib88","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cmi.2014.07.010","article-title":"Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins","volume":"21","author":"de Oliveira","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib90","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib91","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib92","doi-asserted-by":"crossref","first-page":"ofy336","DOI":"10.1093\/ofid\/ofy336","article-title":"Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: a nationwide multicenter study in Taiwan","volume":"6","author":"Lin","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib93","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1111\/1469-0691.12091","article-title":"Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge","volume":"19","author":"Navarro-San Francisco","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib94","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/00365548.2014.923106","article-title":"Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit","volume":"46","author":"Papadimitriou-Olivgeris","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib95","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib96","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","article-title":"Tigecycline: an update","volume":"75","author":"Stein","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.jmii.2022.02.001_bib99","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","article-title":"The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jmii.2022.02.001_bib100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2253-13-13","article-title":"KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients","volume":"13","author":"Di Carlo","year":"2013","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.jmii.2022.02.001_bib101","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jmii.2022.02.001_bib102","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","volume":"46","author":"Balandin Moreno","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib103","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jmii.2022.02.001_bib104","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Caston","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib107","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib108","first-page":"61","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib109","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib110","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib111","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib112","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jmii.2022.02.001_bib113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s15010-021-01577-x","article-title":"Mono vs. combo regimens with novel beta-lactam\/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature","volume":"49","author":"Meini","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2022.02.001_bib114","first-page":"61","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant enterobacteriaceae infections","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jmii.2022.02.001_bib116","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2022.02.001_bib117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib118","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib119","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib121","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/jac\/dkz125","article-title":"Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime\/avibactam","volume":"74","author":"Papadimitriou-Olivgeris","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib122","first-page":"e02097","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British society for antimicrobial chemotherapy\/healthcare infection society\/British infection association joint working party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib124","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2022.02.001_bib125","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York city","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib126","doi-asserted-by":"crossref","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","article-title":"Vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib127","doi-asserted-by":"crossref","first-page":"e02165","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/IDR.S193638","volume":"12","author":"Liao","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/IDR.S194482","article-title":"Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"12","author":"Lai","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib130","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dks084","article-title":"Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies","volume":"67","author":"Cai","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib131","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2022.02.001_bib132","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2022.02.001_bib133","article-title":"European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine)","author":"Paul","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib134","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib135","doi-asserted-by":"crossref","first-page":"105833","DOI":"10.1016\/j.ijantimicag.2019.10.014","article-title":"A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections","volume":"55","author":"Agyeman","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib136","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijantimicag.2018.01.006","article-title":"Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib137","article-title":"Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: a Bayesian network meta-analysis of randomized clinical trials","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jmii.2022.02.001_bib138","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dkt142","article-title":"Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies","volume":"68","author":"Eckmann","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib139","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: a review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jmii.2022.02.001_bib140","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"Vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib141","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jmii.2022.02.001_bib142","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib143","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline","volume":"9","author":"Van Hise","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jmii.2022.02.001_bib144","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/22221751.2020.1769500","article-title":"The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections","volume":"9","author":"Ayobami","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047297","article-title":"Incidence of and risk factors for infection or colonization of vancomycin-resistant enterococci in patients in the intensive care unit","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2022.02.001_bib147","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/1076629041310091","article-title":"Vancomycin-resistant Enterococcus (VRE) carriage and infection in intensive care units","volume":"10","author":"Yeh","year":"2004","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib148","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/jac\/dks181","article-title":"Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis","volume":"67","author":"Lu","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib149","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O'Driscoll","year":"2015","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib151","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In\u00a0vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib152","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.00714-13","article-title":"Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections","volume":"57","author":"Whang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib153","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib154","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib155","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review","volume":"73","author":"Foolad","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib156","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib157","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2016.06.010","article-title":"Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib158","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/IPC.0b013e31827ce847","article-title":"Treatment of vancomycin-resistant enterococcal bacteremia in an observational cohort of neutropenic oncology patients: daptomycin versus linezolid","volume":"21","author":"Barbour","year":"2013","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jmii.2022.02.001_bib159","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/IPC.0b013e31822b7f6e","article-title":"Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia","volume":"19","author":"Bio","year":"2011","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jmii.2022.02.001_bib160","doi-asserted-by":"crossref","first-page":"890 e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib161","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IPC.0000000000000482","article-title":"Comparison of daptomycin and linezolid in the treatment of vancomycin-resistant Enterococcus faecium in the absence of endocarditis","volume":"25","author":"Suleyman","year":"2017","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jmii.2022.02.001_bib162","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.02943-14","article-title":"Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci","volume":"58","author":"Hayakawa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib163","article-title":"Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia","volume":"6","author":"Narayanan","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib164","doi-asserted-by":"crossref","first-page":"e02216","DOI":"10.1128\/AAC.02216-16","article-title":"Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant Enterococcus faecium bacteremia","volume":"61","author":"Britt","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1078155214556523","article-title":"Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus","volume":"22","author":"Patel","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jmii.2022.02.001_bib166","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jmii.2011.11.005","article-title":"Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan","volume":"45","author":"Chou","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib167","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.clinthera.2010.09.008","article-title":"Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study","volume":"32","author":"Crank","year":"2010","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jmii.2022.02.001_bib168","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkp154","article-title":"Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?","volume":"64","author":"Mave","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib169","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jhm.994","article-title":"Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin","volume":"7","author":"Twilla","year":"2012","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jmii.2022.02.001_bib170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, Medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib171","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia","volume":"51","author":"Ye","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib172","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib173","series-title":"CLSI supplement M100","article-title":"Performance standards for antimicrobial susceptibility testing","year":"2019"},{"key":"10.1016\/j.jmii.2022.02.001_bib174","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the clinical and laboratory standards Institute","volume":"70","author":"Satlin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib175","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib176","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib177","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/phar.1922","article-title":"Role of combination antimicrobial therapy for vancomycin-resistant Enterococcus faecium infections: review of the current evidence","volume":"37","author":"Yim","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jmii.2022.02.001_bib178","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41598-018-19986-8","article-title":"A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2022.02.001_bib179","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.clinthera.2015.04.008","article-title":"Clinical outcomes of daptomycin for vancomycin-resistant Enterococcus bacteremia","volume":"37","author":"Moise","year":"2015","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jmii.2022.02.001_bib180","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/AAC.02274-13","article-title":"Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium","volume":"58","author":"Sakoulas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib181","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib182","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-014-0691-4","article-title":"Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria","volume":"43","author":"Heizmann","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2022.02.001_bib183","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2147\/IDR.S208298","article-title":"Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect","volume":"12","author":"Hemapanpairoa","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.02.001_bib184","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diagmicrobio.2013.07.012","article-title":"In\u00a0vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates","volume":"77","author":"Tang","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib185","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib186","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.1924","article-title":"Fosfomycin for the treatment of cystitis in the abdominal solid organ transplant population","volume":"37","author":"Loethen","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jmii.2022.02.001_bib187","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/jac\/dkw178","article-title":"Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis","volume":"71","author":"Seroy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib188","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.45.1.324-326.2001","article-title":"Nitrofurantoin is active against vancomycin-resistant Enterococci","volume":"45","author":"Zhanel","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib189","first-page":"DC19","article-title":"Revisiting nitrofurantoin for vancomycin resistant enterococci","volume":"11","author":"Meena","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jmii.2022.02.001_bib190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mic.2000.106904","article-title":"Epidemiology of bacteriuria caused by vancomycin-resistant enterococci--a retrospective study","volume":"28","author":"Wong","year":"2000","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jmii.2022.02.001_bib191","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1001\/archinte.1996.00440210097010","article-title":"Treatment of vancomycin-resistant Enterococcus faecium infections","volume":"156","author":"Lai","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmii.2022.02.001_bib192","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jinf.2011.08.014","article-title":"Single center experience of a vancomycin resistant enterococcal endocarditis cohort","volume":"63","author":"Forrest","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2022.02.001_bib193","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1345\/aph.1A085","article-title":"In\u00a0vitro assessment of urinary isolates of ampicillin-resistant Enterococci","volume":"36","author":"Williamson","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jmii.2022.02.001_bib194","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2017.06.008","article-title":"Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience","volume":"51","author":"Shah","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.02.001_bib195","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s40506-016-0082-8","article-title":"A clinician's guide to the treatment of vancomycin resistant enterococci bacteremia and endocarditis","volume":"8","author":"Soule","year":"2016","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.jmii.2022.02.001_bib196","first-page":"64","article-title":"Vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.02.001_bib197","article-title":"Ceftaroline: a new cephalosporin with activity against Methicillin-resistant Staphylococcus aureus (MRSA)","volume":"3","author":"Duplessis","year":"2011","journal-title":"Clin Med Rev Therapeut"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:27:12Z","timestamp":1761658032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118222000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":197,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1684118222000251"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2022.02.001","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}